登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>4-1BB >CHEK-ATF073

Human 4-1BB (Luc) HEK293 Reporter Cell

For research use only.

描述(Description)

The Human 4-1BB (Luc) HEK293 Reporter Cell was engineered to not only express NF-κB signaling response element, but also express the receptor full length human 4-1BB (Gene ID: 3604), which can drive luciferase expressing systems by 4-1BB ligand/ agonist antibody stimulation. In the absence of agonist antibody or 4-1BB ligand, the 4-1BB receptor is not activated and luminescence signal is low. In the presence of agonist antibody or 4-1BB ligand, the 4-1BB pathway-activated luminescence can be detected in a dose-dependent manner. This reporter cell can also be used to test agonist antibody whether in an FcγR-dependent manner to strengthen the agonistic activity

应用说明(Application)

Screen for ligands or agonist antibodies that can bind and activate 4-1BB

4-1BB Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

4-1BB FACS

Expression analysis of human 4-1BB on Human 4-1BB (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human 4-1BB (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human 4-1BB antibody.

Protocol

 

Application

4-1BB APPLICATION

Agonistic activity analysis of anti-human 4-1BB antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO or CHO/CD32b. Urelumab, a strong intrinsic agonistic antibody, can activate 4-1BB signaling independent of CD32b-mediated crosslinking. Utomilumab, a weak agonistic antibody, can activate 4-1BB signaling dependent on CD32b-mediated crosslinking.

Protocol

 

Signaling Bioassay

4-1BB SIGNALING

Response to Anti-human 4-1BB antibody (RLU).
The Human 4-1BB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of anti-human 4-1BB antibody. The EC50 was approximately 0.83 μg/mL.

Protocol

4-1BB SIGNALING

Response to Anti-human 4-1BB antibody (FOLD).
The Human 4-1BB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Anti-human 4-1BB antibody. The max induction fold was approximately 98.

Protocol

 

Passage Stability

4-1BB PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human 4-1BB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of Anti-human 4-1BB antibody. Anti-human 4-1BB antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 6-25.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
4-1BB靶点信息
英文全称:Tumor necrosis factor receptor superfamily member 9
中文全称:肿瘤坏死因子受体超家族成员9
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:71详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定